Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Jazz Pharmaceuticals (JAZZ) PT Raised to $206 at BMO Capital
August 8, 2018 7:00 AM EDTBMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $206.00 (from $201.00) while maintaining a Outperform rating.
Analsyt Gary Nachman commented, 'JAZZ reported a solid top and bottom line beat with 2Q revenue of $501mm vs. BMO/consensus $466mm/$470mm, and adj. EPS... More
